Neurocrine Bio. (NBIX) PT Raised to $184 at Needham

Needham analyst Ami Fadia raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $184.00 (from $170.00) while maintaining a Buy rating.

The analyst commented: "Mgt reported a strong 3Q, with EPS of $2.04 coming in ~30% above consensus ($1.59), driven by better-than-expected product performance. Crenessity exceeded expectations by +$30M (+45% vs. cons.), and Ingrezza delivered +$21M (+3% vs. cons.) above consensus. Mgt is again expanding its sales force by ~30% to continue driving Ingrezza volume growth ahead of IRA related pricing pressure for Austedo starting 2027, and to broaden endocrinologist reach for Crenessity. Mgt remains well positioned to drive shareholder value with two scaled commercial assets and a deep, advancing pipeline. We see a catalyst-rich period ahead of YE25, including valbenazine's Ph 3 in dyskinetic cerebral palsy, Ph 2 for NBI-'770 in MDD, R&D day and Austedo's IRA price. We raise our PT, reflecting higher Crenessity sales assumptions and continued commercial momentum."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery